Compare ADMA Biologics Inc (ADMA) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Enbridge Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Enbridge Inc trades at $55.15 (market cap $120.14B). The key difference: Enbridge Inc is far larger — about 56.4× ADMA Biologics Inc's market cap, and Enbridge Inc pays a 5.11% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ENB | |
|---|---|---|
Market Cap | $2.13B | $120.14B |
Sector | Health | Energy |
52-Week High | $20.38 | $58.04 |
52-Week Low | $7.60 | $43.79 |
Enterprise Value | $2.20B | $200.94B |
Dividend Yield | — | 5.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Enbridge (ENB) trades at $55.05, up 1.79% for the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $65.19B in 2025 and a net income margin of 10%, though it missed Q3 2025 EPS estimates. Recent news highlights include a dividend payment of $0.97 and upcoming Q2 2026 earnings on July 31, 2026. Analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains mixed with solid cash flow from operations supporting dividends, but debt levels have risen to 48.81% of assets. Key risks include energy market volatility and execution of growth projects. The stock offers a high yield but faces near-term technical pressure and valuation concerns at a P/E of 25.73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
